Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC By Ogkologos - September 7, 2026 89 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-671 study after 5 years of follow-up Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,... August 15, 2019 EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... October 5, 2021 Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated... January 10, 2022 Alex Trebek Has Completed Chemo And Will Be Back For The... September 11, 2019 Load more HOT NEWS Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated... How Breast Cancer Risk Assessment Tools Work Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in... Progress in Treating Liver Cancer and Biliary Tract Cancer with Immunotherapy:...
